Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Organ bacterial burden in rabbits during treatment.
  • Fig. S2. 11C-rifampin exposures in UB and plasma during treatment.
  • Fig. S3. 11C-rifampin brain/plasma AUC0–30 ratios in UB during treatment.
  • Fig. S4. Rifampin concentration using MS of UB during treatment.
  • Fig. S5. Rifampin concentration by MS in brain and CSF in uninfected control rabbits.
  • Fig. S6. 11C-rifampin brain/plasma AUC0–30 ratios in infected and uninfected control animals.
  • Fig. S7. Plasma 11C-rifampin PET and rifampin MS correlation in patients with TB.
  • Fig. S8. PK–brain biodistribution model goodness of fit in UB in rabbits.
  • Table S1. Rabbit MS results.
  • Table S2. Rabbit 11C-rifampin brain/plasma AUC0–30 ratios.
  • Table S3. Parameter estimates from the rifampin PK enzyme turnover model.
  • Table S4. Studies used for external validation of the plasma PK model.
  • Table S5. Rifampin PK–brain biodistribution model parameter estimates and bootstrap results.
  • Table S6. Projected mean rifampin exposure parameters (AUC0–24h and Cmax) in BLs in children at different weeks of treatment.
  • Table S7. Projected rifampin exposures in the patient with TBM imaged in the current study.
  • References (4659)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S8 (Microsoft Excel format). Primary data.
  • Movie S1 (.mov format). Whole-body 3D reconstruction of 11C-rifampin biodistribution in a rabbit with TBM.